Experts urge use of experimental antibodies in DR Congo to combat Ebola
Advocacy organizations are petitioning the U.S. government to make an experimental Ebola treatment, Mapp Biopharmaceutical’s MBP134, available for clinical trials and emergency use in the Democratic Republic of the Congo (DRC) and Uganda, where a Bundibugyo Ebola outbreak is currently active. The letter was sent to the Biomedical Advanced Research and Development Authority (BARDA) by … Read more